Monitor upcoming Phase 1b data readouts for gamgertamig in autoimmune cytopenias and seropositive diseases, as these are the next catalysts. The BofA stake increase suggests institutional interest but is not a near-term trading signal. No financial guidance or revenue data was provided in this filing.
Price Chart
Executive Summary
Lakefront Biotherapeutics announced two developments on August 24, 2026: the FDA granted Orphan Drug Designation to gamgertamig for pemphigus, expanding its regulatory momentum beyond AIHA and ITP; and Bank of America crossed the 10% voting rights threshold, now holding a 10.11% stake via voting rights and derivatives. The orphan designation is a modest positive for the pipeline, while the BofA stake increase signals institutional accumulation, but neither event provides near-term revenue or clinical data catalysts.
Key Facts
- FDA granted Orphan Drug Designation to gamgertamig for pemphigus, adding to prior designations for AIHA and ITP.
- Gamgertamig is in Phase 1b studies for autoimmune cytopenias and seropositive autoimmune diseases; proof-of-concept basket studies planned.
- Bank of America crossed above 10% voting rights threshold on August 18, 2026, now holding 10.11% of 65,897,071 outstanding shares.
- BofA's position includes 2.15% direct voting rights and 7.96% equivalent financial instruments (mostly rights to use and swaps).
- Gamgertamig is in-licensed from Keymed Biosciences, which retains Greater China rights.
Financial Impact
No financial figures disclosed. Orphan Drug Designation provides market exclusivity and development incentives but no direct revenue. BofA's 10.11% stake represents approximately 6.66M shares/equivalents; no transaction value disclosed.
Risk Factors
- Gamgertamig is still in early-stage clinical development; Phase 1b data may not support advancement to registrational studies.
- Orphan Drug Designation does not guarantee clinical or commercial success; competitive landscape for pemphigus treatments is evolving.
- BofA's position includes derivative instruments (swaps, rights to use) that may not reflect long-term conviction; could be delta-hedging or financing activity.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (LKFT) — Batch item 1 | 0001171843-26-005729 |
| Document: 0001171843-26-005729-index-headers.html | 0001171843-26-005728 |
| Document: 0001171843-26-005729-index.html | 0001171843-26-005729 |
| Document: 0001171843-26-005729.txt | 0001171843-26-005729 |
| 6-K Filing (LKFT) — Batch item 5 | 0001171843-26-005728 |
| Document: 0001171843-26-005728-index-headers.html | 0001171843-26-005729 |
| Document: 0001171843-26-005728-index.html | 0001171843-26-005729 |
| Document: 0001171843-26-005728.txt | 0001171843-26-005729 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | 6-K | $30.58 | awaiting T+20 | — | $31.69 (+3.63%) |
Oct 14, 2026 12d ago | 6-K | $29.93 | awaiting T+20 | — | $31.69 (+5.88%) |
Oct 13, 2026 13d ago | 6-K | $29.40 | awaiting T+20 | — | $31.69 (+7.79%) |
Oct 6, 2026 20d ago | 6-K | $30.00 | awaiting T+20 | — | $31.69 (+5.63%) |
Sep 1, 2026 7w ago | 6-K | $28.81 $29.65 | ▲ +2.92% | ▲ +3.25% | $31.69 (+10.00%) |
Aug 25, 2026 8w ago | 6-K | $29.70 $30.72 | ▲ +3.43% | ▲ +2.46% | $31.69 (+6.70%) |
Aug 12, 2026 10w ago | 6-K | $27.93 $26.81 | ▼ −4.01% | ▼ −2.11% | $31.69 (+13.46%) |
Jul 28, 2026 12w ago | 6-K | $27.72 $29.16 | ▲ +5.19% | ▲ +0.17% | $31.69 (+14.32%) |
Jun 30, 2026 16w ago | 6-K | $29.60 $27.72 | ▼ −6.35% | ▼ −4.17% | $31.69 (+7.06%) |
Jun 24, 2026 17w ago | 6-K | $29.01 $28.78 | ▼ −0.79% | ▼ −2.73% | $31.69 (+9.24%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers